Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome
Another Positive Read-Out For A Clinical-Stage Reata Drug
Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints in a first-year interim analysis of the Phase III CARDINAL study in patients with Alport syndrome, an inherited form of chronic kidney disease (CKD).
You may also be interested in...
Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.